Tom Stargardt
Stargardt, Tom 1979-
VIAF ID: 232561707 (Personal)
Permalink: http://viaf.org/viaf/232561707
Preferred Forms
- 100 1 _ ‡a Stargardt, Tom ‡d 1979-
- 100 0 _ ‡a Tom Stargardt
4xx's: Alternate Name Forms (2)
5xx's: Related Names (4)
- 510 2 _ ‡a Hamburg Center for Health Economics ‡4 affi ‡4 https://d-nb.info/standards/elementset/gnd#affiliation ‡e Affiliation
- 510 2 _ ‡a HelmholtzZentrum München ‡4 affi ‡4 https://d-nb.info/standards/elementset/gnd#affiliation ‡e Affiliation
- 510 2 _ ‡a Ludwig-Maximilians-Universität München ‡b Fakultät für Betriebswirtschaft ‡4 affi ‡4 https://d-nb.info/standards/elementset/gnd#affiliation ‡e Affiliation
- 510 2 _ ‡a Universität Hamburg ‡b Fakultät Wirtschafts- und Sozialwissenschaften ‡4 affi ‡4 https://d-nb.info/standards/elementset/gnd#affiliation ‡e Affiliation
Works
Title | Sources |
---|---|
Authors' response to "Health service expenditures and efficiencies in Greece" (I). | |
Availability of and access to orphan drugs: an international comparison of pharmaceutical treatments for pulmonary arterial hypertension, Fabry disease, hereditary angioedema and chronic myeloid leukaemia | |
Blood donation and donors: insights from a large German teaching hospital (2008-2017) | |
Bürgerversicherung die Wirkung von Kopfprämien auf den Arbeitsmarkt | |
[Consensus statement: Management of oral anticoagulation for stroke prevention in patients with nonvalvular atrial fibrillation]. | |
Correction to: Attitudes of physicians from 10 European countries on adherence and how treatment modalities in ABSSSI affect adherence: results from a Delphi survey | |
Cost effectiveness of drug-eluting stents in acute myocardial infarction patients in Germany: results from administrative data using a propensity score-matching approach | |
Cost-effectiveness of hybrid PET/CT for staging of non-small cell lung cancer. | |
Cost-utility analysis comparing heavy-weight and light-weight mesh in laparoscopic surgery for unilateral inguinal hernias | |
Cost-utility analysis of a potential lung cancer screening program for a high-risk population in Germany: A modelling approach | |
Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis | |
Cost-Utility Analysis of Telemonitoring Interventions for Patients with Chronic Obstructive Pulmonary Disease | |
Cost-Utility of Internet-Based Cognitive Behavioral Therapy in Unipolar Depression: A Markov Model Simulation | |
Costs and outcomes of the German disease management programme (DMP) for chronic obstructive pulmonary disease (COPD)-A large population-based cohort study | |
Costs and quality of hospitals in different health care systems: a multi-level approach with propensity score matching | |
Cross-country comparisons of costs: the use of episode-specific transitive purchasing power parities with standardised cost categories | |
Determining the "Health Benefit Basket" of the Statutory Health Insurance scheme in Germany: methodologies and criteria | |
The diffusion of generics after patent expiry in Germany | |
Do discontinuities in marginal reimbursement affect inpatient psychiatric care in Germany? | |
Economic Burden and Quality-of-Life Effects of Chronic Lymphocytic Leukemia: A Systematic Review of the Literature | |
The Economic Burden of Cystic Fibrosis in Germany from a Payer Perspective | |
Economic evaluation of PET and PET/CT in oncology: evidence and methodologic approaches | |
The economic impact of Marfan syndrome: a non-experimental, retrospective, population-based matched cohort study | |
Effect of type of insurance and income on waiting time for outpatient care | |
Effectiveness and costs of flupentixol compared to other first- and second-generation antipsychotics in the treatment of schizophrenia | |
European COvid Survey (ECOS) technical report | |
Fear of hypoglycaemia: defining a minimum clinically important difference in patients with type 2 diabetes | |
Focus on designing health care structures and services for rare diseases | |
A framework to evaluate the effects of small area variations in healthcare infrastructure on diagnostics and patient outcomes of rare diseases based on administrative data | |
Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia | |
Health-economic evaluation of home telemonitoring for COPD in Germany: evidence from a large population-based cohort | |
Health service costs in Europe: cost and reimbursement of primary hip replacement in nine countries. | |
Impact of cross-reference pricing on pharmaceutical prices: manufacturers' pricing strategies and price regulation. | |
The impact of drug quality ratings from health technology assessments on the adoption of new drugs by physicians in Germany | |
Impact of Guidelines on the Diffusion of Medical Technology: A Case Study of Cardiac Resynchronization Therapy in the UK | |
The impact of physician-level drug budgets on prescribing behavior | |
The impact of reference pricing on switching behaviour and healthcare utilisation: the case of statins in Germany | |
Management im Gesundheitswesen Das Lehrbuch für Studium und Praxis | |
Measuring Cost and Analyzing Hospital Performance | |
Measuring the relationship between costs and outcomes the example of acute myocardial infarction in German hospitals | |
Methods to determine reimbursement rates for diagnosis related groups (DRG): a comparison of nine European countries | |
Modelling pharmaceutical price changes in Germany: a function of competition and regulation | |
Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19 | |
Performance of compliance and persistence measures in predicting clinical and economic outcomes using administrative data from German sickness funds. | |
Pharmaceutical Pricing in Germany: How Is Value Determined within the Scope of AMNOG? | |
Preferred supplier contracts in post-patent prescription drug markets | |
Preis des Rauchens Eine Analyse für Deutschland | |
Price of Smoking | |
Pricing behaviour of pharmacies after market deregulation for OTC drugs: the case of Germany. | |
Reforms in the Greek pharmaceutical market during the financial crisis | |
Reimbursement of pharmaceuticals: reference pricing versus health technology assessment | |
Service quality and perceived customer value in community pharmacies | |
The trade-off between costs and quality of care in the treatment of psychosomatic patients with somatoform pain disorder | |
Treatment and Secondary Prevention of Venous Thromboembolism - Change in Oral Anticoagulation | |
United but divided: Policy responses and people's perceptions in the EU during the COVID-19 outbreak | |
User engagement and the role of mHealth in self-management of diabetes: Real-world evidence from the Cornerstones4Care® app |